FRAMINGHAM, MA--(Marketwire - February 07, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced the completion of its IoGen™ Phase III pivotal trial. The study, conducted by physicians throughout the U.S., is designed to evaluate the effectiveness of IoGen, a treatment which may be the first FDA-approved, non-hormonal therapy for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).
